Estela Rodriguez: Underreported toxicity of myopathy from EGFR TKIs

Estela Rodriguez shared a post by Stephen V Liu, on X:

“Important to study under reported toxicity of myopathy from EGFR TKIs as more patients get treated in the adjuvant setting. – can definitely impact QOL.”

Quoting Stephen V Liu‘s post:.

“Myopathy is an underappreciated toxicity of the EGFR TKI osimertinib. In my experience, more of a later event. In this Journal of thoracic oncology report, biopsy suggests a non-inflammatory mechanism. May impact myocyte protein synthesis and mitochondrial dysfunction.”

Read further.
Source: Estela Rodriguez/X and Stephen V Liu/X

Estela Rodriguez is Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. She is board certified in medical oncology and hematology. She has a special interest in the early detection of lung cancer and increasing access to clinical trials. Dr. Rodriguez is known to help empower women to take charge of their own healthcare and believes in the power of mentorship.   

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies.

His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.